Both are GLP-1 receptor agonists; they are not the same molecule. Tirzepatide is a dual GIP/GLP-1 agonist; semaglutide is a single GLP-1 agonist. Tirzepatide produces larger weight loss on average; semaglutide has broader cardiovascular and renal outcome evidence (SELECT, FLOW).
Side-by-side
| Dimension | Semaglutide | Tirzepatide |
|---|---|---|
| Editorial score | 0/100 | 0/100 |
| Semaglutide | Wegovy / Ozempic / compounded | Zepbound / Mounjaro / compounded |
| Tirzepatide | — | — |
Who should pick Semaglutide
Patients whose priorities include FDA-approved cardiovascular event reduction (SELECT), kidney protection in T2D+CKD (FLOW), or the broader outcome evidence base.
Who should pick Tirzepatide
Patients whose priority is maximum weight loss effect, or patients with moderate-to-severe OSA + obesity (Zepbound is the only FDA-approved drug for OSA).
Frequently asked
Is tirzepatide just stronger semaglutide?
No. Tirzepatide is a dual GIP/GLP-1 receptor agonist — different molecule, different mechanism. The added GIP component likely explains tirzepatide's larger weight effect.
Which is safer?
Both have similar safety profiles in trials. Choice should be based on indication and individual response.
Can you switch?
Yes, with clinical supervision. Patients sometimes switch based on tolerance or response.